These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 21122860

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects.
    Kappelle PJ, Lambert G, Dahlbäck B, Nielsen LB, Dullaart RP.
    Atherosclerosis; 2011 Feb; 214(2):492-4. PubMed ID: 21122852
    [Abstract] [Full Text] [Related]

  • 4. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P, Stenman UH, Gylling H.
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [Abstract] [Full Text] [Related]

  • 5. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
    Nekaies Y, Baudin B, Kelbousi S, Sakly M, Attia N.
    J Diabetes Complications; 2015 Sep; 29(8):1165-70. PubMed ID: 26412029
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.
    Constantinides A, Kappelle PJ, Lambert G, Dullaart RP.
    Arch Med Res; 2012 Jan; 43(1):11-4. PubMed ID: 22300679
    [Abstract] [Full Text] [Related]

  • 9. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M, Ishihara M, Yuasa Y, Makino H, Yanagi K, Tamanaha T, Kishimoto I, Kujiraoka T, Hattori H, Harada-Shiba M.
    J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes.
    Vergès B, Duvillard L, Brindisi MC, Gautier E, Krempf M, Costet P, Cariou B.
    Atherosclerosis; 2011 Nov; 219(1):342-8. PubMed ID: 21889145
    [Abstract] [Full Text] [Related]

  • 12. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
    Costet P, Hoffmann MM, Cariou B, Guyomarc'h Delasalle B, Konrad T, Winkler K.
    Atherosclerosis; 2010 Sep; 212(1):246-51. PubMed ID: 20619837
    [Abstract] [Full Text] [Related]

  • 13. Proprotein convertase subtilisin/kexin type 9 (PCSK9), soluble lectin-like oxidized LDL receptor 1 (sLOX-1) and ankle brachial index in patients with differentiated thyroid cancer.
    Ozkan C, Akturk M, Altinova AE, Cerit ET, Gulbahar O, Yalcin MM, Cakir N, Balos Toruner F.
    Endocr J; 2015 Sep; 62(12):1091-9. PubMed ID: 26490048
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects.
    Kwakernaak AJ, Lambert G, Dullaart RP.
    Clin Biochem; 2012 Nov; 45(16-17):1522-4. PubMed ID: 22809551
    [Abstract] [Full Text] [Related]

  • 17. The effect of insulin on circulating PCSK9 in postmenopausal obese women.
    Awan Z, Dubuc G, Faraj M, Dufour R, Seidah NG, Davignon J, Rabasa-Lhoret R, Baass A.
    Clin Biochem; 2014 Aug; 47(12):1033-9. PubMed ID: 24721682
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study.
    Noguchi T, Kobayashi J, Yagi K, Nohara A, Yamaaki N, Sugihara M, Ito N, Oka R, Kawashiri MA, Tada H, Takata M, Inazu A, Yamagishi M, Mabuchi H.
    Atherosclerosis; 2011 Jul; 217(1):165-70. PubMed ID: 21411093
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.